# Evaluating tumor chemosensitivity: a head-to-head comparison of the prognostic value of KELIM (modeled CA125 elimination rate constant K) and RECIST 1.1 (radiological response valuation criteria in solid tumors) in ovarian cancer

## TL;DR

This study compares two methods for predicting ovarian cancer patient outcomes but finds neither is strongly linked to survival.

## Contribution

The novel contribution is a direct comparison of KELIM and RECIST 1.1 as chemosensitivity indicators in ovarian cancer prognosis.

## Key findings

- No significant association was found between KELIM and overall survival.
- RECIST 1.1 response also did not significantly influence patient survival.
- Larger, more homogeneous studies are needed to confirm these results.

## Abstract

The aim of the study was to analyze KELIM (modeled CA125 ELIMination rate constant K) and RECIST 1.1. (radiological response valuation criteria in solid tumors) as indicators of tumor chemosensitivity and their role in predicting patient prognosis.

This retrospective single-center analysis included 165 consecutive patients with advanced newly diagnosed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer who underwent surgical and chemotherapeutical treatment at the Department of Gynecologic Oncology.

There were significant differences in OS between the neoadjuvant and adjuvant groups of patients (20.87 vs 32.88 months). There was a significant difference in the response to treatment assessed in imaging studies between the groups, with higher rates of complete and partial responses to treatment among PDS patients (p = 0.002). However, upon a separate analysis of the NACT and PDS subgroups, the multivariate analysis showed no significant influence of KELIM and RECIST 1.1. response on patients’ overall survival of patients.

Our findings showed no significant associations between KELIM, RECIST and overall survival of patients. However, further studies on bigger homogenous population samples are required to confirm our findings.